Real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir for the treatment of chronic hepatitis C 1b genotype infection in China
10.3760/cma.j.issn.1007-3418.2019.02.010
- VernacularTitle: 奥比帕利联合达塞布韦用于中国基因1b型丙型肝炎病毒慢性感染的真实世界研究
- Author:
Yusheng JIE
1
;
Jing YUAN
2
;
Xiaohong ZHANG
1
;
Yujuan GUAN
3
;
Zhixin ZHAO
1
;
Yutian CHONG
1
;
Ling TAO
1
;
Jianping LI
3
;
Chaoshuang LIN
1
Author Information
1. The Third Affiliated hospital of Sun Yat-sen university, Guangzhou 510630, China
2. The Third People’s Hospital of Shenzhen, Shenzhen 518118, China
3. The Eighth People’s hospital of Guangzhou, Guangzhou 510060, China
- Publication Type:Journal Article
- Keywords:
Hepatitis C, chronic;
Direct-acting antiviral agent;
Real-world research
- From:
Chinese Journal of Hepatology
2019;27(2):123-127
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the real-world safety and curative effect of ombitasvir combined with dasabuvir for the treatment of chronic hepatitis C 1b genotype infection in non-cirrhotic or compensated cirrhotic patients.
Methods:A real-world research method was adopted, and the research was conducted at three medical centers of mainland China. Non- cirrhotic or compensated cirrhotic patients with HCV genotype 1b infection who were initially treated with IFN/PEG-IFN-alpha combined with ribavirin, and ombitasvir combined with dasabuvir for 8 or 12 weeks were taken. Sustained virological response (SVR) and the incidence of adverse events during treatment and follow-up were evaluated after 12 weeks of drug withdrawal at OBV/PTV/r 25/150/100mg once daily and DSV 250mg, twice daily. Median and range were used for description of non-normally distributed data.
Results:80 cases of GT1b were included in this study. Of these 88.8% (71/80) were newly diagnosed, 12.5% (10/80) were compensated cirrhotic, 97.5% (78/80) received 12 weeks treatment, and 2.5% (2/80) received 8 weeks treatment. The rate of HCV RNA negative at EOT (end of treatment) was 100% (64/64). A total of 67 patients completed the treatment within 12 weeks, and 43 patients returned to the hospital for further consultations, and SVR12 was 100%(43/43). No patient discontinued the drugs because of an adverse event during treatment.
Conclusion:In the real world, Ombitasvir combined with dasabuvir for the treatment of chronic hepatitis C 1b genotype infection in China has 100% rates of EOT and SVR12 with well- tolerability and safety.
